• About us
  • Core Technology
  • Bio-Service
  • Investors
  • Careers
中文 English
  • About us
    • Introduction
    • Information
      • Announcement
      • Events
    • Management Team
      • Members
      • Consultants
    • Contact us
  • Core Technology
    • New medicine development platform
      • Skin diseases
      • metabolic diseases
      • Anti-inflammation
      • Diseases related to deficient mitochondrion
      • Others
  • Bio-Service
    • Scientific products
      • Western Blot
      • Cell Culture Supplement
      • Protein Isolation
      • Protein Quantification
      • Dyes and Buffer
    • Supplier
      • Lumiprobe
      • Rigaku Reagents
    • Service
      • Quantitative MS and systematic biological analysis experiment service
      • Protein identity certification experiment service
      • Microarray and biological information analysis experiment service
  • Investors
  • Careers

About us

    • >
  • About us
    • >
  • Information
    • >
  • Announcement
  • Introduction
  • Information
    • Announcement
    • Events
    • Corporate image
  • Management
    • Members
    • Consultants
  • Contact us
2024-10-04
EB Receives Notification from CRO Regarding IND Submission to TFDA for Phase I Clinical Trial of ENERGI-F705PD, an Oral Treatment for Parkinson's

Energenesis Biomedical CO., LTD has submitted an application to the TFDA for the Phase I clinical trial of ENERGI-F705PD, an oral treatment for Parkinson's Disease, in Taiwan.

back
  • +886-2-26270835
  • +886-2-26270836
  • 6F.-3, No.21, Ln.583, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan (R.O.C.)
Copyright © 2017 ENERGENESIS BIOMEDICAL CO., LTD. All Rights Reserved. Design by choice